INTRODUCTION
Methotrexate (MTX)' and l-,8-D-arabinofuranosylcytosine (Ara-C) are chemotherapeutic agents often used together for the treatment of human neoplasms. Considerable controversy exists over whether these drugs are synergistic (1) (2) (3) or antagonistic (4-6) when given together or sequentially.
One focus of attention has been the change in deoxycytidine triphosphate (dCTP) pools after MTX. This occurs because the phosphorylation of Ara-C by deoxycytidine kinase can be inhibited by dCTP (7, 8) . Therefore, drugs which would lower dCTP pools would be expected to produce greater quantities of Ara-C monophosphate (Ara-CMP) and ultimately Ara-C triphosphate (Ara-CTP), the lethal form of Ara-C, and to be synergistic in their antitumor activity. Conversely, drugs which produced greater quantities of dCTP would be expected to generate less Ara-CTP and to be antagonistic when given with Ara-C. Also, because both nucleotides dCTP and Ara-CTP compete for DNA polymerase, alterations of these nucleotides can affect the inhibition of this enzyme by Ara-CTP (9) .
This study was designed to examine the biological and biochemical consequences of MTX and Ara-C combinations in L1210 and human leukemic cells.
METHODS
Cells. L1210 murine leukemia cells were maintained as suspension culture in Fischer's medium plus 10%o horse serum, transferred twice weekly, and kept at 37°C in a 5% CO2 atmosphere. After obtaining informed consent, blood from untreated human leukemic patients was collected in heparinized tubes by venipuncture, suspended in equal volumes of 3% dextran, and sedimented at a 450 angle for 30 min to remove erythrocytes. Microscopic examination of the separated leukemic cells revealed a 1% persistence of erythrocytes. Separated erythrocytes did not appreciably concentrate Ara-C with or without MTX pretreatment; therefore, this 1% contamination does not significantly alter the validity ofthe experiments subsequently performed. The leukemic cells were transferred into incubation medium composed of 80% Fischer's culture medium, 10% 1.25 M Hepes buffer (pH 7.4), and 10% horse serum to achieve a cell concentration of 5 x 107 cells/ml.
Drugs. MTX was provided by the Drug Development Branch of the National Cancer Institute, Bethesda, Md. Ara-C was obtained from The Upjohn Co., Kalamazoo, Mich.
[3H-(G)]Ara-C (13.2 mCi/mmol) and [6-3H] deoxyuridine (UdR) (21.9 Ci/mmol) were purchased from New England Nuclear, Boston, Mass. [3',5',9(n)-3H]MTX (17 Ci/mmol) was procured from Amersham Corp., Arlington Heights, Ill.
Cloning. The biological antitumor effect of MTX and Ara-C was determined by cloning L1210 cells in soft agar by the technique we previously reported (10) . After appropriate single drug exposure, the suspension culture was centrifuged at 100 g for 5 min at 37°C. The drug-containing supernate was discarded, the cell pellet was resuspended in drug-free Fischer's medium, and then recentrifuged as before. This washing procedure was repeated twice to remove any extracellular drug before cloning. In sequential drug studies, the second drug was added to the cell suspension after a variable exposure to the first drug. After the designated time, the washing sequence was repeated and the cells placed in cloning medium.
The cloning procedure involved placing 100 cells into 10-ml culture tubes which contained 2 ml of liquified agar (37°C) and 3 ml of drug-free Fischer's medium that contained 10% horse serum. The tubes were capped and placed upright and incubated at 37°C in a 5% C02 atmosphere. The agar-medium solution was of such viscosity as to prevent cell settling. Viability was defined by a cell's ability to divide and produce progeny, which after 7 d were visible as individual cell colonies or clones. Percent viability, then, is the ratio of'clones formed from drug-treated suspension cultures to clones formed from untreated cultures times 100. The cloning ef'ficiency of L1210 in this system was 85%.
Nucleotide pools. The ribonucleotide pools were evaluated of logarithmically growing L1210 cells (100 ml at 2-4
x 105 cells/ml) exposed to 3 h of MTX at concentrations from 0.01 to 100 ,uM. After exposure to MTX, Ara-C (1.1 MLCi/nmol) was added, achieving a concentration of 0.5 ,uM. 1 h later, the cells were centrifuged at 1,000 g for 10 min at 4°C, the supernate discarded, and the cell pellet washed twice with 0.9% NaCl at 4°C before being precipitated in 2 ml of 10% TCA. The supernate that contained the ribonucleotides was extracted three times with 6 ml of ether to remove the TCA and stored at -20°C until all samples could be evaluated on the same day. Separation of the triphosphate ribonucleotides was by high-pressure liquid chromatography on a Du Pont model 640 system (Du Pont Co., Instruments Div., Wilmington, Del.) with a linear gradient (0.01-1.0 M) of sodium phosphate buffer (pH 3.31) with a flow rate of 0.9 ml/min on a 25-cm x 4.6-mm Partisil SAX (10 Am particle size) column. Absorbance was recorded at 254 and 280 nm, and 30-s collections were obtained for radiochromatogram correlations. The data is expressed as picomoles of Ara-CTP per 106 cells. dCTP and deoxythymidine triphosphate (dTTP) isolation and quantitation were performed by the method of Solter and Handschumacher (11) . Suspension cultures of L1210 cells dividing at a logarithmic rate were studied after a 3-h exposure to MTX (0.01-100 MM).
UdR incorporation. Logarithmically growing L1210 cells were centrifuged as before and resuspended to a cell concentration of 1-5 x 107 cells/ml. At designated times after adding [3H]UdR (21.9 Ci/mmol), 0.04 ml of the cell suspension was placed in harvesting plates (Microbiological Associates, Walkersville, Md.) and automatically suctioned onto glass filter strips by use of'a MASH cell harvester (Microbiological Associates). The acid-insoluble fraction was then precipitated on the filter strips with a 10-ml solution of 10% TCA and washed twiced with distilled H20 to remove any nonprecipitated label. After room drying, the cell-precipitated areas were placed in glass minicounting vials, 3 ml of OCS added (Amersham Corp.), and radioactivity quantitated with a liquid scintillation spectrometer. Drug uptake studies. 0.01-100 MLM of MTX was added to suspension cultures of L1210 in logarithmic growth (inoculated at 1 x 104 cells/ml and used at 2-5 x 105 cells/ml). After 1, 3, and 6 h, 250 ml of the cell suspension was centrifuged at 100 g for 5 min. The drug-containing supernate was then used to resuspend the cells to a 6-ml vol at a concentration of _3 x 107 cells/ml. This cell suspension was placed in a 25-ml stoppered flask and incubated in a 37°C shaker water bath. A 0.3-ml solution of [3H]Ara-C (1.1 MuCi/nmol) was then added, giving a final Ara-C concentration of0.5 uMM. 1 ml ofthe cell suspension was removed at designated times and centrifuged at 1,000 g for 5 min in a Wintrobe sedimentation tube. The supernate was removed, and radioactivity was determined in a 0.2-ml sample (drug in medium). The inside of the tube that contained the cell pellet was washed gently twice without disturbing the cell pellet with 0.9% NaCl at 4°C to remove any radioactivity remaining on the side walls of the tube. The undisturbed cell pellet was then precipitated with 0.5 ml of 3.5% HCl04, releasing the intracellular radiolabeled drug into this supernate which was removed after repeat centrifugation of cellular debris at 1,000 g for 5 min, and radioactivity was determined in a 0.1-ml samiiple (drug in cells). The ratio of' intracellular drug was calculated as previously described by Handschumacher and Fischer (12) after appropriate corrections for drug loss from the cell pack during the washing procedure and for the interstitial space of the cell pack which had drug-containing medium. The fraction of the cell pellet which contained medium was 30% of'the cell pack volume as deter- The intracellular accumulation of [3H]Ara-C is expressed both as the ratio of the concentration of Ara-C inside the cells to that in the medium and as picomiioles per 106 cells. Approximately 90% of the intracellular Ara-C is in the form of nucleotide derivatives; only 10% being the unmnetal)olized nucleoside, Ara-C.
Free intracellular MTX. L1210 suspension cultures were exposed to MTX (0.01-100 MuM) for variable times dturing logarithmic growth (250( ml at 2-5 x 105 cells/mil). The cells were separated f'rom the drtug-containing mediumni by centriflging at 1,000 g for 10 min at 4°C. 1.0( ml ofa Tris/KCI soluition (0.05 M/0.1 M, pH 7.0), which contained 10% glycerol, was added to the cell pellet. The cells in this suspension were lysed, releasing intracellular MTX into the solution by f'reezethawing three times. The cellular debris was sedimiented by centrifuging at 10,000g for 10 min. The stupernate was removed, and the (juantity of unbouind or free intracellular MTX (MTXf) was determined by the enzymatic inhibition of dihydrofolate reductase (DHFR) method previoutsly described (13) . The same enzymatic method was used to determiinle the specific activity of DHFR. Proteini content was established by the method of Lowry et al. (14) .
RESULTS

L1210 cells
Cloning. The biological antitumor eff'ect of' MTX and Ara-C was evaluated in the soft agar cloning systeimi.
Antitumor Activity of Methotrexate and Cytosine Arabinoside 78'3
When MTX was present in the suspension culture at 0.1, 1, and 10 ,uM for 9 h before cloning in drug-free medium, the resulting percent viability was 100, 50, and 20%, respectively. Administration of Ara-C (1 AM) for 1 h before cloning resulted in 100% cell viability; when MTX was present in the suspension culture from 1 to 8 h before the 1-h exposure to Ara-C, the result was a greater killing of cells (Fig. 1 ). When Ara-C preceded the MTX for 1 h, viability was identical to that observed with MTX alone. Enhanced Ara-C entry. One mechanism of this synergism in cell kill might be enhanced accumulation of Ara-C in MTX-treated cells. The accumulation rate of Ara-C into the acid-soluble fraction of cells was examined. A 1-h exposure to MTX (1 IAM) did not alter the Ara-C accumulation from the control rate. However, after a 3-h exposure to MTX (1 ,uM) the rate of Ara-C accumulation was twice that of the control rate. Ara-C accumulation was increased further to three times the control rate after a 6-h exposure to MTX (1 IuM) (Fig. 2) .
Similar experiments were done after a 3-h exposure to MTX at concentrations from 0.1 to 100 ,uM. With increasing MTX concentrations there was an increasing rate ofaccumulation of Ara-C. Of note, however, is that the rate of Ara-C accumulation was actually less than (15, 16) , it would be expected that the augmentation of Ara-C uptake by MTX might also require MTXf. During the experiment outlined in Fig. 3 , MTXf was examined. MTXf was only present when extracellular concentrations of MTX were 1, 10, and 100 uM. The relationship between these free intracellular levels of MTX and the rate of Ara-C accumulation in cells is presented in Fig. 4 . Augmentation of Ara-C accumulation did not occur until free intracellular levels of MTX were present (MTXf).
To help establish that MTXf is necessary for enhanced Ara-C uptake, the MTXf was allowed to efflux from cells by transferring them to drug-free medium. MTX (10 ,uM) was added to logarithmically growing suspension cultures of L1210 cells. After a 3-h exposure to this concentration of MTX, the cells were removed from the MTX-containing medium, washed twice with 0.9% NaCl, and then resuspended in drug-free medium.
[3H]Ara-C accumulation into the acid-soluble fraction was determined without washing the cells, immediately after this washing procedure, and 1, 2, and 3 h later. Increasing amounts of MTXf effluxed out of the cells with time. As seen in Fig. 5 miultst be presenit fo(r enhanced initracelltilar acciiumulatioi of Ara-C to occur. To reconifirml that this ohservation of enhanicecl [V3H]Ara-C acctiilatioii in cells and the clegree of inhihition of the conversion of dUMIP to dTNIP occtur at the sam11e conicentrationi of NITX, the relatioinship FIGURE 6 Viability of L l_ l( following ITX (M) (10lNI) aid Ara-C (A) (1 AM): The effect of removing cells from NITXtolutuillilng illediumil before iddinig Ara-C. Repeat cloninlg experimients xere donie in triplicate tw ice as described in Fig. 1 . The iabilitx after a 3-anid 5-h exposuLre to MTX was 85 anld 87/% respettivelv. The viabilitv after 2 h of Ara-C was 85%. Wb hen MITX aind Ara-C were added simnultaneously for a dlurationi of h before cloniing, the xiabilitv decreased to 55%.
If the Ara-C were added f'or 2 h after a 3-h pretreatmenit of \ITX, the viabilitx was clecreased exven fLrther to 30%. However, if the cells which hacd been exposed to MTX for 3 h xwere washed free of their MITX-containing Iniedilimi anid placed im druLg-free mlediumiii for 2 h before the additioni to a 2-h expoSuLre to Ara-C, the xiability rose to 8.5%. This reversal of the sx ynergistic killinig of cells after the removal of cells fromii the MITX-contaisning imiediiium conifirms the biochemical information presented in Figs. 4 and 5: MTXf is iecessary for maximuim killing oftcells xhetn Ara-C is given after MITX. of MTXf and inhibition of [3H]UdR incorporation into acid-insoluble material was determined (Fig. 8) .
The maximum inhibition of UdR incorporation into acid-insoluble material also occurred with 100 ,uM MTX in the medium and 8 ,uM of MTXf. Another method of examining the necessity of MTXf for maximum inhibition of the coversion of dUMP to dTMP is to quantitate dTTP. Inhibition of DHFR by MTX prevents THF production; because of this reduced methyl donor pool (THF) the conversion of dUMP to dTMP is reduced, and, therefore, a reduction in dTTP follows. L1210 cells exposed to MTX (0.01-100 ,uM) for 3 h were studied. The intracellular pools of dTTP did not decrease until 10 and 100 ,M of MTX had been given (Table I) . There is little doubt that the greatest inhibition of dTMP synthesis occurs when the levels of MTXf are greatest. Therefore, a general correlation exists between the concentration of MTX required to reduce dTTP pools and that required to enhance Ara-C accumulation. As previously mentioned, earlier studies reporting antagonism of MTX and Ara-C were performed with concentrations of MTX in the medium that would be insufficient to result in MTXf levels and maximally inhibit dTMP synthesis.
Nucleotide pools
The lethal form of Ara-C is the triphosphorylated derivative, Ara-CTP. This nucleotide inhibits DNA polymerase and is considered to be the major site of action of Ara-C (17) (18) (19) . The initial phosphorylation of Ara-C upon entry into the cell is to Ara-CMP by deoxycytidine kinase (7, 8) . dCTP can influence the MTX at the doses indicated was added to logarithmically growing suspension cultures of L1210 (3 x 105 cells/ml), and after 3 h dTTP, dCTP, and Ara-CTP were quantitated as outlined in Methods. The maximum decrease of dTTP and dCTP occurred after 10 and 100 ,uM of MTX, which were also the conditions yielding the highest Ara-CTP levels. The maximum range from the mean values shown was +5%.
initial phosphorylation step of Ara-C by inhibiting deoxycytidine kinase (7, 8) and also compete with Ara-CTP for DNA polymerase. Therefore it is important to evaluate alterations in Ara-CTP and dCTP pools in the context of MTX pretreatment. Ara-CTP levels were determined in L1210 cells exposed for 3 h to varying concentrations of' MTX. Separation and isolation of Ara-CTP was achieved by high-pressure liquid chromatography and (quantified by determining the radioactivity present in the fractions collected in the region of the Ara-CTP. Ara-CTP was markedly increased (eightf'old) in those cells exposed to 100 ,tM of MTX and to a lesser extent at lower concentrations of MTX (Table I) . Recovery of radiolabel was 99%, with 90% of this present in the nucleotide derivatives Ara-CMP, Ara-C diphosphate, and Ara-CTP.
The changes in the dCTP pools were biphasic. When concentrations of extracellular MTX were 0.01, 0.1, and 1 ,uM, dCTP values actually increased, but when MTX was 10 and 100 ,uM the dCTP pools decreased (Table I) . A logical interaction of these two triphosphorylated nucleotides, Ara-CTP and dCTP, could help explain the synergistic killing observed in the initial cloning experiments (Fig. 1) and the accumulation of' Ara-C into these cells. Specifically, after 0.01 and 0.1 ,uM MTX, the elevated dCTP pools could have inhibited deoxycytidine kinase and, therefore, the initial phosphorylation of Ara-C to Ara-CMP. This could explain the observed decrease of Ara-C accumulation in cells exposed to MTX at these lower concentrations. The markedly enhanced accumulation of' Ara-C in cells exposed to 10 and 100 ,uM of' MTX could partially be the consequence of the decreasing dCTP pools and, subsequently, of' less inhibition of deoxycytidine kinase.
Similarly, because both Ara-CTP and dCTP would be competing for DNA polymerase, the greatest inhibition of this enzyme would occur when the Ara-CTP was maximally increased and the dCTP was maximally decreased, precisely the situation when cells are exposed to 100 ,uM of MTX. Therefore, MTX is both antagonistic and synergistic with respect to Ara-C, dependent upon the pretreatment concentration of MTX.
Human leukemia cells
The eff'ect of' these interactions between MTX and Ara-C are usef'ul clinically if' the same alterations described in L1210 cells also occur in human cancer cells. Two patients with rapidly increasing acute myelogenous leukemic cell numbers were evaluated. The first patient received 1 g/M' MTX in a phase II study examining the efficacy of'high doses of MTX. Immediately before the MTX injection, and 2 h later, peripheral blood was obtained by venipuncture, and the leukemic cells were removed as described in Methods. The inhibition of' [3H]UdR into acid-insoluble material was determined to be certain that this dose of' MTX did, in f'act, inhibit methyl transf'er to dUMP. The intracellular accumulation of[3H]Ara-C in these leukemic cells was perf'ormed as with L1210 cells above. The result was an enhanced entry and accumulation of' [3H]Ara-C (Fig. 9) . The second patient did not receive MTX, but rather the leukemic cells were removed and separated as bef'ore.
One-half'the cells were exposed f'or 4 h to MTX (1 ,M), and the remaining one-half'served as controls. The cells incubated in MTX-containing medium had an augmented [3H]Ara-C entry (Fig. 10) , theref'ore the augmentation of accumulation ofAra-C in human leukemic cells does occur after high doses of MTX. This presumably would lead to enhanced or synergistic killing of cells, however, this could not be evaluated with any certainty in these patients and must remain a presumption.
DISCUSSION
MTX and Ara-C are synergistic in killing L1210 cells when MTX precedes Ara-C. This phenomenon is dependent upon the dose of extracellular MTX and time of exposure before adding Ara-C. This sequential drug synergism is most likely the consequence of the enhanced intracellular accumulation of Ara-C which occurs after MTX treatment. Enhanced Ara-C accumulation occurred with those concentrations of MTX which induced inhibition of methyl transfer to dUMP and reduced dTTP production, which was dependent upon achieving increased MTXf. The maximum enhancement of Ara-C accumulation in cells was only observed at doses of MTX which resulted in the highest MTXf. This fact probably accounts for the confusing reports previously recorded by others evaluating the interaction of MTX and Ara-C, because the doses used in these communications were insufficient to produce .
The consequence ofusing high doses of MTX (10 and 100 uM) which might account for the observed antitumor synergism between MTX and Ara-C is twofold. First, at these doses of MTX, the levels of intracellular Ara-CTP, the lethal form of Ara-C, is increased considerably (eightfold, after a 3-h exposure to 100 ,uM of MTX). Second, after following these same high doses of MTX, the dCTP pools are decreased. The importance of this latter finding is that dCTP is a feedback inhibitor of deoxycytidine kinase, the enzyme responsible for the initial phosphorylation of Ara-C to Ara-CMP (7, 8) , and the dCTP also competes with Ara-CTP for DNA polymerase (9) . It is therefore not surprising that the maximum synergistic activity of these two drugs occurred when 100 ,M of MTX preceded Ara-C, the condition in which there were both increased quantities of Ara-CTP and decreased quantities of dCTP.
Given the maximum doses of MTX used in these studies (10 and 100 AM), which inhibited nearly completely [3H]UdR incorporation into the acidinsoluble fraction, it would be expected that the concentrations ofdTTP should approach zero. This was not observed, nor have others documented these theoretically low levels after inhibitory doses of MTX (20, 21 (21, 22) . A logical explanation is lacking. However, the lowered dCTP pools that resulted after the higher doses of MTX (10 and 100 ,uM) are probably the result of the deamination of deoxycytidine nucleotides. Maley and Maley (23) have demonstrated that dTTP is an effective inhibitor of deoxycytidylate deaminase and that ['4C]deoxycytidine could readily be incorporated into DNA thymidine of rat embryos. Fridland (20) has recently documented that the major contribution to the increasing dUMP pools in response to MTX inhibition are the deoxycytidine nucleotides. A probable explanation for the lowered dTTP and dCTP pools at these high doses of MTX is that the decrease in dTTP after MTX results in greater deamination of the deoxycytidine nucleotides to deoxyuridylate. Therefore, the major effect of MTX on Ara-C accumulation may be mediated by these alterations of dTTP and dCTP.
An unusual aspect of the Ara-C accumulation is that the rate of accumulation was linear up to 102 min. Most drugs reach saturable levels within 60 min, and our MTX uptake experiments were saturable by 45 min.
However, these unusual kinetics with Ara-C have been observed and reported previously. Chu and Fischer (24) found a linear accumulation of radiolabeled Ara-C in L5178Y cells up to 4 h. Their cells, like ours, were in logarithmic growth (3 x 105 cells/ml) and the concentration of Ara-C (3.3 ,MM) was also similar to ours.
We have also performed experiments with L5178Y cells and found that the biochemical alterations induced by MTX and subsequent Ara-C accumulations are nearly identical to those in L1210 cells. The explanation of this prolonged linear Ara-C uptake may be related to the fact that Ara-C accumulation, which is a consequence of the phosphorylation of this drug, is only occurring significantly in those cells which are in DNA synthesis. Only in these cells would the MTX have the effects described on dTTP and dCTP. In individual cells, Ara-C accumulation may indeed be saturable, but as the fraction of the total cell population which enters DNA synthesis increases, Ara-C accumulation of' the entire population of cells increases. Because the doubling time of L1210 cells is 12 h, one could expect that the maximum quantity of Ara-C accumulated in the total cell population might not be achieved until all cells have reached the DNA synthesis portion of their cell cycle, or 12 h. For example, MTX, whose intracellular accumulation is limited by membrane transport and which is independent of cell cycle, is saturable by 45 min.
It is important to recognize from these studies that this augmented Ara-C accumulation, which is dependent upon MTXf, can be reversed by allowing the MTXf to efflux from the cells and also by administering leucovorin in doses which reverse inhibition by MTX of [3H]UdR incorporation into the acidinsoluble cell fraction. The clinical correlation of this observation is obvious. If synergistic killing of human cancer cells is to occur, high doses of MTX must be given which result in MTXf in tumor cells; then Ara-C would be administered before the MTXf effluxes from the cells and also before leucovorin rescue is given.
Augmentation ofAra-C accumulation in human acute myelogenous cells occurred after high doses of MTX paralleling our observations of MTX-enhanced Ara-C accumulation in L1210 cells. Because MTX is an S-phase specific drug, one would expect that the synergistic interactions between MTX and Ara-C would primarily occur in cells undergoing active DNA synthesis. The augmentation of Ara-C accumulation in plateau-phase L1210 growth cells was only a 20% enhancement as compared with the eightfold enhancement in logarithmically growing cells-a finding consistent with this hypothesis. Therefore, this drug combination would not be expected to be nearly as useful for the treatment of' tumors with a small growth fraction as it would be for those tumors with a high growth fraction, such as rapidly proliferating leukemia or lymphoma. We have, in fact, employed this information in designing drug therapy which includes high doses of MTX followed by high doses of Ara-C for the treatment of diffuse histiocytic lymphoma. Toxicity has been minimal.
Administration of high doses of MTX, when preceding ARA-C, results in enhanced killing of rapidly growing L1210 cells. The biochemical consequences ofthis drug sequence are lower dCTP pools and higher Ara-CTP levels, which can account for the synergistic antitumor effects.
